NEW YORK – Guardant Health said Friday that it has entered a new partnership with Meaningful Insights Biotech Analytics (MiBA) that pairs Guardant's biomarker testing data and MiBA's analytics to advance precision medicine across the MiBA Network.
The companies said that they hope to drive personalized, data-driven approaches that facilitate broad, consistent access to innovative treatments that can enhance patient outcomes.
"Our partnership with MiBA allows us to deliver a multidimensional view of what is driving cancer, using real-world data, to empower healthcare providers and patients to take a more personalized approach to cancer care," Steven Collora, Guardant Health's senior VP of key accounts and strategic initiatives, said in a statement.
"By leveraging our technology and data insights, we can enhance understanding and accessibility of genomic testing, ensuring that every patient receives the precise care recommended in clinical guidelines," added Mark Moch, one of MiBA's two managing partners.
MiBA describes itself as a hub that collects and refines genomic and clinical information, insurance claims, and pharmaceutical and clinical trials data to ease and accelerate the spread of precision medicine.
In addition to its deal with Guardant, the firm recently announced a collaboration with Foundation Medicine to aid the firm in promoting educational programs on comprehensive genomic profiling for certain practices within the American Oncology Network.
MiBA has also partnered with the National Community Oncology Dispensing Association to launch the Oncology Insights Program, which aims to provide healthcare professionals with curated information and targeted education to enhance data-driven decision-making.